MG
WHWK

Michael Gelband’s Whitehawk Therapeutics WHWK Stock Holding History

Michael Gelband’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-307,759
Closed -$1.49M – 2146
2023
Q3 		$1.49M Buy
307,759
+171,248
+125% +$995K 0.01% 798
2023
Q2 		$934K Buy
136,511
+34,676
+34% +$270K 0.01% 1130
2023
Q1 		$737K Buy
101,835
+26,510
+35% +$283K 0.01% 1237
2022
Q4 		$966K Buy
75,325
+17,795
+31% +$232K 0.01% 962
2022
Q3 		$813K Buy
57,530
+16,364
+40% +$215K 0.01% 1190
2022
Q2 		$507K Sell
41,166
-2,706
-6% -$40.2K 0.01% 1342
2022
Q1 		$745K Buy
+43,872
New +$841K 0.01% 1319
2021
Q3 		– Sell
-1,001
Closed -$25K – 2749
2021
Q2 		$25K Buy
+1,001
New +$22.9K ﹤0.01% 2253

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Michael Gelband's WHWK Position: Q4 2023 in Review

Michael Gelband sold out of Whitehawk Therapeutics (WHWK) in Q4 2023, closing a stake of 307,759 shares — an estimated $1.49M sold.

Michael Gelband first reported a position in WHWK in Q2 2021 and held it in 8 quarters. The position peaked at $1.49M in Q3 2023. 65 funds tracked by Wall St. Rank hold WHWK as of Q4 2023.

  • Michael Gelband reported no remaining Whitehawk Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Michael Gelband sold 307,759 Whitehawk Therapeutics shares in Q4 2023, an estimated $1.49M.
  • Michael Gelband first reported a position in Whitehawk Therapeutics in Q2 2021 and held it in 8 quarters.
  • Michael Gelband's Whitehawk Therapeutics position peaked at $1.49M in Q3 2023.
  • 65 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2023.

Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.